Haisco and Lilly Forge $3B Deal to Advance New Medicines
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
